Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease (NCT06529822)
Phase 1 Clinical Trial of a Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease
🩺 Plain-English Summary (8th-Grade Level)
This is a phase 1 clinical trial to evaluate the safety, feasibility and immunogenicity of a personalized cancer vaccine strategy in patients with solid tumors and molecular residual disease. The hypothesis of the trial is that synthetic long peptide personalized cancer vaccines will be safe and capable of generating measurable neoantigen-specific T-cell responses enabling ctDNA clearance. The personalized cancer vaccines are composed of synthetic long peptides corresponding to prioritized cancer neoantigens and will be co-administered with poly-ICLC.
Who can join: Review the eligibility criteria below.
Location: AdventHealth — Orlando, Florida
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (3 Sites)
- AdventHealth — Orlando, Florida
- Washington University School of Medicine — St Louis, Missouri
- Ohio State University — Columbus, Ohio
📞 Contact the Study Coordinator
Phone: (314) 747-0072
Email: gillanders@wustl.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Muscle-Invasive Bladder Carcinoma
- A Study of Risk Enabled Therapy After Neoadjuvant Immunochemotherapy for Bladder Cancer — Chapel Hill, North Carolina
- Prophylactic Antibiotics in Cystectomy With Diversion — Minneapolis, Minnesota
- Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors — Santa Monica, California
- Bladder Preservation for Patients With Muscle Invasive Bladder Cancer (MIBC) With Variant Histology — Los Angeles, California
- NEO-BLAST: Neoadjuvant Therapy for Bladder Cancer Followed by Active Surveillance vs Treatment — Vancouver, British Columbia
Explore by condition: All Muscle-Invasive Bladder Carcinoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.